Summit Therapeutics Inc (SMMT)

Over the past six months, Summit Therapeutics' stock experienced several notable events. In May 2025, top-line results from the HARMONi trial showed ivonescimab combined with chemotherapy significantly reduced the risk of disease progression or death in EGFR-mutated NSCLC patients, and ivonescimab received NMPA approval in China. In September 2025, detailed results from the HARMONi trial were provided, and data from the HARMONi-6 Phase III trial in China was showcased at ESMO 2025. In October 2025, Summit Therapeutics reported its Q3 2025 earnings, missing the consensus estimate, which led to a stock price drop, and corporate insiders made significant stock purchases. The company plans to submit a BLA for ivonescimab in the U.S. in Q4 2025. Overall, the stock has declined approximately 15.94% over the past six months.

Demand seasonality for Summit Therapeutics' products is linked to the underlying diseases they target. Clostridioides difficile infection (CDI) exhibits seasonality, with peaks in late winter or early autumn, potentially affecting demand for ridinilazole. The market for non-small cell lung cancer (NSCLC) treatments is characterized by continuous growth, with no significant demand seasonality.

Summit Therapeutics, Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing medicinal therapies to improve the lives of patients. Their lead candidate, ivonescimab, is a bispecific antibody for non-small cell lung cancer (NSCLC) and is undergoing Phase III trials globally and is approved in China. The company is also advancing ridinilazole, an oral antibiotic in Phase III trials for Clostridioides difficile infection (CDI).

Summit Therapeutics is headquartered in Miami, Florida, and has offices in Menlo Park, California; Princeton, New Jersey; Oxfordshire, UK; and Dublin, Ireland. Its license territories for ivonescimab include the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa. Ivonescimab is also approved in China through a partnership.

Summit Therapeutics achieved "Great Place to Work® Certification™" for November 2024 to November 2025, indicating a positive work environment. No specific external events significantly impacting Summit Therapeutics' brand reputation beyond clinical trial results and financial reporting were prominently reported in the past year.

Summit Therapeutics is primarily owned by institutional shareholders (13.82%) and company insiders (174.27%), with a smaller percentage held by retail investors (0.00%). Major institutional owners include Baker Bros. Advisors LP, Vanguard Group Inc., Fmr LLC, BlackRock, Inc., State Street Corp, and Price T Rowe Associates Inc. Significant individual insider owners include Mahkam Zanganeh, who owns 86.05% of the company, and Robert W. Duggan, owning 81.42%.